

COVID-19 Reimbursement Rate for Vaccine Administration Code 0004A Effective Sept. 22, 2021

November 29, 2021

What is New

Effective October 7, 2021, for dates of services on or after September 22, 2021, the <u>reimbursement rates for COVID-19</u> vaccine administration procedure code 0004A were implemented for Texas Medicaid.

<u>Affected claims</u> with code 0004A, if any are identified, will be reprocessed. Providers are not required to appeal the claims unless they are denied for additional reasons after the claim reprocessing is completed.

New Benefit

Effective for dates of service on or after September 22, 2021, in accordance with the U.S. Food and Drug Administration (FDA) issuance of an Emergency Use Authorization (EUA) for the use of <u>COVID-19 Vaccine administration code 0004A</u> is now a benefit of Medicaid. Procedure Code 0004A, the single booster dose of the Pfizer-BioNTech COVID-19 vaccine, should be administered at least six months after completion of the primary series in:

- Individuals 65 years of age and older
- Long-term care facility residents
- Individuals 18 through 64 years of age with underlying medical conditions
- Individuals 18 through 64 years of age at increased risk of exposure and transmission due to occupational or institutional setting

Note: Procedure code M0201 (COVID-19 vaccine administration inside a patient's home) can be billed in the home setting with procedure code 0004A.

Vaccine Administration claims submission information:

Vaccine Code	Vaccine Administration Codes	Labeler Name
91300 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID- 19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular	0004A -Single dose Booster	Pfizer, Inc.



What's Reimbursed

The federal government is currently purchasing Janssen (Johnson and Johnson). It's providing Janssen to states to distribute to health care providers at no cost for COVID-19 treatment. We won't reimburse for Janssen that providers received for free. Providers should not charge members for the treatment. We will **reimburse for the administration of the treatment**. Other medically necessary treatment for COVID-19 will be covered consistent with the terms of the member's benefit plan. When providers begin to purchase Janssen, we will update our position. Reference CMS Medicaid toolkit For more details

Resources

Enrolling as a COVID-19 vaccinator
COVID-19 Vaccine Information
COVID-19 Vaccine Booster Shots

CMS Medicaid Toolkit - Coverage and Reimbursement of COVID-19 Vaccines, Vaccine Administration and Cost Sharing under Medicaid, the Children's Health Insurance Program, and Basic Health Program

Questions

For more information, call the TMHP Contact Center at 1-800-925-9126 or the TMHP CSHCN Services Program Contact Center at 1-800-568-2413.

CPT Copyright 2021 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

The above material is for informational purposes only and is not a substitute for the independent medical judgment of a physician or other health care provider. Physicians and other health care providers are encouraged to use their own medical judgment based upon all available information and the condition of the patient in determining the appropriate course of treatment. The fact that a service or treatment is described in this material is not a guarantee that the service or treatment is a covered benefit and members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any service or treatment is between the member and their health care provider.

Blue Cross and Blue Shield of Texas, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association

Revised: 11232021